A new study presented at this year’s American College of Allergy, Asthma and Immunology Annual Scientific Meeting highlights the need for mental health support in patients with atopic dermatitis (AD).
This article was originally published by Dermatology Times®. It has been lightly edited.
Almost three-quarters of patients with atopic dermatitis (AD) experience mental health distress associated with their health condition, according to a new study presented at this year’s American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting.1
Allison Loiselle, PhD, of the National Eczema Association, and colleagues recruited adults aged 18 and older with AD, as well as caregivers of youth patients aged 8 to 17 years old from October through November 2022. A total of 954 participants completed an online survey to share their experiences.
According to the study results, mental health concerns are prevalent in patients with AD, yet they may not be communicating this with clinicians. Specifically, 72.6% of patients experienced poor mental health symptoms for 1 to 10 days within the preceding month.
About one-fifth of participants (17.7%) indicated a more chronic nature of their mental health symptoms, with symptoms lasting more than 11 days. Less than one-half of patients (42.5%) had been asked about their mental health by their clinician, and about one-third of the respondents noted they did not disclose their symptoms with their clinicians. Consequently, less than half of the patients (45.1%) received referrals for mental health care services or other supports.
Patient receiving support for mental health
Image credit: rawpixel.com - stock.adobe.com
This study supports recent research exploring the link between patients' mental health, well-being, and AD. Earlier this year, the results of a comprehensive literature search on improving psychological health outcomes in children found psychological well-being was directly related to objective disease severity. Furthermore, the researchers noted improvements in psychological well-being were directly correlated with improvements in disease severity.2
Fortunately, behavioral interventions can also improve both the itch-scratch cycle as well as the psychological sequelae associated with AD. There is evidence that hypnotherapy, biofeedback, and mindfulness therapy can support patients and result in improvements.
“People who don’t suffer with AD don’t understand how debilitating it can be,” Loiselle said in a press statement.3 “In addition to the terrible itching and dry, cracked skin, there are often sleep disruptions, and broader impacts on quality of life and overall well-being. Depression and anxiety are among the symptoms of those who deal with AD and the chronic, unpredictable nature of this condition.”
Tamara Hubbard, MA, LCPC, explained in a press statement that “AD-related quality of life impacts can include social impairment, emotional and behavioral problems, and significant psychological problems, including depression, anxiety, and suicidal ideation." Hubbard works with parents of children with allergies and added that the “relentless itching” and AD’s negative effects on appearance can also take a toll on patients.
“It’s important for patients and health care providers to discuss mental health concerns and to be aware of resources and trained mental health professionals who can help," Hubbard said.
References
1. Loiselle A, Johnson J, Begolka WS. Atopic dermatitis patient experience with discussing and addressing mental health concerns with allergists. Poster presented at: 2023 ACAAI Annual Scientific Meeting; November 9-13, 2023; Anaheim, California.
2. Mostafa N, Smith SD. Improving psychological health outcomes in children with atopic dermatitis. Clin Cosmet Investig Dermatol. 2023;16:2821-2827. doi:10.2147/CCID.S393254
3. Survey: 72% of eczema patients suffered poor mental health symptoms for 1-10 days in past month. News release. ACAAI; November 9, 2023.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More